Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Syndax Pharmaceuticals’s reported figures.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026. Open the filing →
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
FAQ
- What is Syndax Pharmaceuticals's EBIT?
- Syndax Pharmaceuticals (SNDX) reported EBIT of -$34.2M in Q1 2026.
- How has Syndax Pharmaceuticals's EBIT changed year-over-year?
- Syndax Pharmaceuticals's EBIT increased by 59.2% year-over-year, from -$83.76M to -$34.2M.
- What is the long-term trend for Syndax Pharmaceuticals's EBIT?
- Over 4 years (2021 to 2025), Syndax Pharmaceuticals's EBIT has grown at a 79.6% compound annual growth rate (CAGR), from $26.22M to -$273.08M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Syndax Pharmaceuticals's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude